Not every device letter comes from CDRH

FDA’s warning-letter portal has no field marked device or drug. It has an issuing office column, and every letter, whatever it is about, is filed under whichever FDA center wrote it. For most device firms that distinction never matters — a device warning letter comes from the Center for Devices and Radiological Health, full stop. For a combination-product manufacturer, it is the whole gap.

What the pipeline actually keeps

FDA Radar’s warning-letter adapter pulls every posted letter from FDA’s own datatables endpoint — no upstream filter, all offices, every week. The filtering happens on our side, in one function, against one literal string: a letter is kept only if its issuing-office cell contains “Center for Devices and Radiological Health.” Anything else — the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, an Office of Regulatory Affairs district — is discarded before a single field of it is normalized. There is no “filtered but visible” state for these, the way a low-relevance item still reaches the corpus under a label. A non-CDRH letter never becomes an item. It never becomes a row.

Why that line doesn’t track “about a device”

A combination product doesn’t pick its issuing office by what it contains. Under 21 CFR Part 3, FDA assigns a combination product to a lead center based on its primary mode of action — the constituent part expected to make the greatest contribution to the product’s therapeutic effect. An autoinjector, a prefilled syringe, a drug-eluting catheter can all be assigned to CDER if the pharmacological action leads, even though a physical device constituent part sits inside every one of them and has to be manufactured to device-quality standards regardless.

Manufacturing oversight follows the same split. FDA’s own compliance program for combination-product inspections describes inspections as CDER-led or CDRH-led, and 21 CFR 4.4 lets a manufacturer build a streamlined quality system on either a drug-based or a device-based foundation, adding the other system’s provisions on top. A drug-led combination product routinely runs under a CDER-led inspection program while its quality system still has to answer for device-style CAPA, complaint handling, and design-control requirements — the same violation themes that fill a CDRH letter’s subject line. When FDA writes that letter, the issuing office on it reads CDER. Nothing about its content does.

The letter can cite a failed design-verification record or an unclosed CAPA and still never say “Center for Devices and Radiological Health” anywhere in it. Our filter reads that one field, not the subject line.

The practice

A firm safe from this gap is a firm with no combination products anywhere in its portfolio, or its contract manufacturers’. Everyone else — a device constituent inside a CDER-led drug-device combination, a device-led combination that still occasionally draws a CBER or ORA letter on a biologic-adjacent line — should treat FDA Radar’s warning-letter coverage as CDRH coverage, precisely as described on what we monitor and how often, and watch the relevant firm directly against FDA’s full warning-letter listing for anything issued under another center’s name. This is regulatory intelligence about where one pipeline draws its line, never regulatory advice about which center will end up inspecting any specific combination product.